待处理
入排:排除
图源:待检查
Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108.
Fred Saad, Paula Del Rosario, Noel W Clarke
Eur Urol 85(6) e178-e179
摘要
摘要
无摘要
KM 提取结果
0 个 Figure · 0 个 KM 面板